Twin Protocol CEO Stacey Engle Honored as a Puget Sound Business Journal's 2025 40 Under 40 Honouree
Seattle, WA, April 24, 2025 (GLOBE NEWSWIRE) — Twin Protocol, a pioneer in the development of ethically engineered, personalized artificial intelligence (AI) technology today announced that the company's CEO, Stacey Engle has been named to the Puget Sound Business Journal's prestigious 40 under 40 list for 2025. Engle, a trailblazer in AI and blockchain, is celebrated for her visionary leadership in advancing ethical technology, and for shattering barriers as a female executive.
Engle is an AI pioneer, championing a human perspective in technology while advocating for responsible AI implementation. As co-founder and CEO of Twin Protocol, she leads the charge to revolutionize knowledge sharing and monetization through secure, decentralized AI Twins. These AI Twins merge cutting edge AI and blockchain to empower individuals and organizations. Her work prioritizes privacy, inclusion and human-centric design, ensuring technology serves as a force for collective progress.
Her expertise is rooted in a distinguished career bridging business acumen and disruptive tech. Prior to Twin Protocol, she served as President of the largest privately held women-owned leadership company, advising Fortune 2000 companies and continually earning recognition on the Inc. 5000 Fastest-Growing Companies list. Engle's unique perspective is further shaped by her dual roles as a groundbreaking tech executive and a devoted mother, offering a rare lens on balancing innovation with empathy.
'This recognition is a testament to the incredible team at Twin Protocol and our shared mission to build technology that uplifts humanity,' said Engle. ''As both a leader and a parent, I believe innovation must be anchored in ethics. The tools we create today will shape the world our children inherit, so we build with integrity, intention, and the future in mind.'
Celebrating Leadership and Vision
Engle will be featured in the Puget Sound Business Journal's special 40 Under 40 print edition on April 25 and honored at an awards reception on April 24 at Seattle's Alaska Care Retreat. The annual list spotlights rising leaders under 40 who are reshaping the Puget Sound region's business landscape.
About Twin Protocol
Twin Protocol ('Twin') offers an innovative solution that redefines personal presence by creating unique AI twins that capture an individual's expertise. It provides a platform where knowledge is preserved, shared, and evolves, offering 24/7 access to mentorship and insights from industry leaders, visit https://twinprotocol.com/.
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
19 minutes ago
- Yahoo
Centuri Holdings (CTRI) Surged This Week. Here is Why.
The share price of Centuri Holdings, Inc. (NYSE:CTRI) surged by 9.74% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. A close-up of an electrical power line with a bright blue sky in the background, highlighting the company's selection of electricity and natural gas services. Centuri Holdings, Inc. (NYSE:CTRI) is a strategic utility infrastructure services company that partners with regulated utilities to build and maintain the energy network that powers millions of homes and businesses across the United States and Canada. Centuri Holdings, Inc. (NYSE:CTRI) continues to surge after the company announced $350 million in new customer awards in late May, reflecting strong demand for the company's infrastructure solutions across North America. The awards span the United States and include work supporting electric and gas infrastructure modernization, water relocation, utility distribution, and renewables. This comes after Centuri Holdings had already announced nearly $490 million in multi-year customer awards earlier this year. The share price of Centuri Holdings, Inc. (NYSE:CTRI) has gained almost 23% over the last month. While we acknowledge the potential of CTRI as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 minutes ago
- Yahoo
Array Technologies (ARRY) Gained Over 11% This Week. Here is Why.
The share price of Array Technologies, Inc. (NASDAQ:ARRY) surged by 11.78% between May 29 and June 5, 2025, putting it among the Energy Stocks that Gained the Most This Week. Let's shed some light on the development. An aerial view of a solar panel farm, its panel incremented tracking the sun's path. Array Technologies, Inc. (NASDAQ:ARRY) is a leading global provider of solar tracking technology to utility-scale and distributed generation customers, who construct, develop, and operate solar PV sites. Array Technologies, Inc. (NASDAQ:ARRY) fell by over 20% last month after investors reacted negatively to President Trump's sweeping tax and spending bill advancing through the House of Representatives, which may result in the termination of numerous subsidies that have supported the renewable energy sector. The bill is expected to have devastating consequences for the booming solar industry, which relies heavily on such credits. So ARRY's recent rebound could be due to investors flocking in to purchase the stock at a lower, more attractive price. Moreover, it must be mentioned that Array Technologies, Inc. (NASDAQ:ARRY) posted strong results in its Q1 2025 last month, beating forecasts in both revenue and earnings. Moreover, the company achieved the second-largest quarter of volume shipped since 2023 and maintained its guidance for the full year 2025. While we acknowledge the potential of ARRY as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 10 Cheap Energy Stocks to Buy Now and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
25 minutes ago
- Yahoo
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory
We came across a bullish thesis on Regeneron Pharmaceuticals, Inc. (REGN) on Notes From The Beauty Contest's Substack. In this article, we will summarize the bulls' thesis on REGN. Regeneron Pharmaceuticals, Inc. (REGN)'s share was trading at $605.39 as of 29th May. REGN's trailing and forward P/E were 15.39 and 17.39 respectively according to Yahoo Finance. A scientist in a lab conducting research on cell-based therapeutics and biotechnology. Regeneron's latest earnings report was notably weak, with a 3.7% revenue decline and a 14% EPS drop, surprising given the company's history of exceeding market expectations. The primary driver was a steep 26% year-over-year decline in the U.S. Eylea franchise, particularly a 39% drop in 2mg Eylea sales. This was partly due to a co-pay assistance funding gap, which forced many Medicare patients to switch to cheaper alternatives like compounded Avastin, impacting both Regeneron and rival Roche's Vabysmo. Regeneron, having contributed over $400 million last year to charitable foundations supporting co-pay assistance, is now seeking to share this burden, proposing a matching donation program to encourage broader industry support. Another setback was the FDA's Complete Response Letter delaying approval of the Eylea-HD pre-filled syringe, a key product needed to compete with Vabysmo. The delay stemmed from third-party component issues rather than drug efficacy, and management believes resolution could be near. Margins also contracted, with gross margin falling from 89% to 85% due to unspecified inventory write-offs, possibly related to older Eylea 2mg or even leftover REGEN-COV stock. However, the margin pressure appears more tied to one-offs and increased R&D spending than structural issues. On a more positive note, Regeneron's pipeline is broadening meaningfully. Itepekimab, an IL-33 antibody, shows promise as a major respiratory asset with pivotal COPD data upcoming and expanded trials underway. The growing RNAi pipeline, now at nine siRNAs through its Alnylam collaboration, signals Regeneron's potential evolution beyond antibodies into a broader genetic medicine powerhouse. Regeneron Pharmaceuticals, Inc. (REGN) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 66 hedge fund portfolios held REGN at the end of the first quarter which was 68 in the previous quarter. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Sign in to access your portfolio
